B. Furr and V. Jordan, The pharmacology and clinical uses of tamoxifen, Pharmacology & Therapeutics, vol.25, issue.2, pp.127-205, 1984.
DOI : 10.1016/0163-7258(84)90043-3

V. Jordan, Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer, British Journal of Pharmacology, vol.279, issue.Suppl, 2006.
DOI : 10.1038/sj.bjp.0706399

L. Wickerham, Tamoxifen ??? An Update on Current Data and Where it Can Now be Used, Breast Cancer Research and Treatment, vol.75, issue.S1
DOI : 10.1023/A:1020353530963

G. Goldenberg and E. Froese, Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro, Cancer Res, vol.42, issue.12, pp.5147-5151, 1982.

E. Gelmann, Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma, Semin Oncol, vol.24, issue.1, 1997.

D. Medina, P. Favre, G. Poirot, and M. , Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study, Current Medicinal Chemistry-Anti-Cancer Agents, vol.4, issue.6, pp.491-508, 2004.
DOI : 10.2174/1568011043352696

URL : https://hal.archives-ouvertes.fr/inserm-00090772

R. Carroll, J. Zhang, K. Dashner, M. Sar, P. Black et al., Steroid Hormone Receptors in Astrocytic Neoplasms, Neurosurgery, vol.37, issue.3, pp.496-504, 1995.
DOI : 10.1227/00006123-199509000-00019

H. Khalid, A. Yasunaga, M. Kishikawa, and S. Shibata, Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors, Cancer, vol.23, issue.10, pp.2571-2578, 1995.
DOI : 10.1002/1097-0142(19950515)75:10<2571::AID-CNCR2820751026>3.0.CO;2-U

M. Assimakopoulou, G. Sotiropoulou-bonikou, T. Maraziotis, and J. Varakis, Does sex steroid receptor status have any prognostic or predictive significance in brain astrocytic tumors?, Clin Neuropathology, vol.17, issue.1, pp.27-34, 1998.

V. Jr, . Ft, R. Selker, I. Pollack, V. Arena et al., The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of 'failed' patients, Neurosurgery, vol.30, issue.6, pp.897-903, 1992.

M. Cloughesy, R. Woods, K. Black, W. Couldwell, R. Law et al., Prolonged treatment with biologic agents for malignant glioma: A case study with high dose tamoxifen, Journal of Neuro-Oncology, vol.35, issue.1, pp.39-45, 1997.
DOI : 10.1023/A:1005895616377

A. Brandes, M. Ermani, S. Turazzi, E. Scelzi, F. Berti et al., Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study, Journal of Clinical Oncology, vol.17, issue.2, pp.645-650955, 1996.
DOI : 10.1200/JCO.1999.17.2.645

S. Top, A. Vessieres, G. Leclercq, J. Quivy, J. Tang et al., Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormoneindependent breast cancer cell lines Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro, Chem Eur J J Med Chem, vol.948, issue.2112, pp.5223-52363937, 2003.

E. Hillard, A. Vessieres, L. Thouin, G. Jaouen, and C. Amatore, Ferrocene-Mediated Proton-Coupled Electron Transfer in a Series of Ferrocifen-Type Breast-Cancer Drug Candidates, Angewandte Chemie International Edition, vol.44, issue.2, pp.285-290, 2006.
DOI : 10.1002/anie.200502925

U. Schatzschneider and N. Metzler-nolte, New Principles in Medicinal Organometallic Chemistry, Angewandte Chemie International Edition, vol.3, issue.10, pp.1504-1507, 2006.
DOI : 10.1002/anie.200504604

B. Rosenberg, V. Camp, L. Krigas, and T. , Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, Nature, vol.3, issue.4972, pp.698-699, 1965.
DOI : 10.1038/205698a0

P. Dyson, G. Sava, A. Nguyen, V. Marsaud, C. Bouclier et al., Metal-based antitumour drugs in the post genomic era Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment, Dalton Trans Int J Pharm, vol.22347, issue.1612, pp.1929-1933128, 2006.

B. Heurtault, P. Saulnier, B. Pech, J. Proust, and J. Benoit, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-880, 2002.
DOI : 10.1023/A:1016121319668

G. Jaouen, S. Top, A. Vessieres, G. Leclercq, J. Quivy et al., The first organometallic antioestrogens and their antiproliferative effects, Comptes Rendus de l'Acad??mie des Sciences - Series IIC - Chemistry, vol.3, issue.2, pp.89-93, 2000.
DOI : 10.1016/S1387-1609(00)00118-3

K. Mccarthy, D. Vellis, and J. , Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue, The Journal of Cell Biology, vol.85, issue.3, pp.890-902, 1980.
DOI : 10.1083/jcb.85.3.890

T. Mosmann, A. Vonarbourg, C. Passirani, P. Saulnier, P. Simard et al., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake, J Immunol Methods J Biomed Mater Res A, vol.65, issue.27, pp.55-63, 1983.

B. Heurtault, P. Saulnier, B. Pech, M. Venier-julienne, J. Proust et al., The influence of lipid nanocapsule composition on their size distribution, European Journal of Pharmaceutical Sciences, vol.18, issue.1, pp.55-61, 2003.
DOI : 10.1016/S0928-0987(02)00241-5

A. Vonarbourg, P. Saulnier, C. Passirani, J. Benoit, Y. Bouligand et al., Electrokinetic properties of noncharged lipid nanocapsules: Influence of the dipolar distribution at the interface New lipid nanocapsules exhibit sustained release properties for amiodarone, Electrophoresis J Control Release, vol.2684, issue.1112, pp.2066-207559, 2002.

A. Malzert-fréon, S. Vrignaud, P. Saulnier, V. Lisowski, J. Benoit et al., Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent, International Journal of Pharmaceutics, vol.320, issue.1-2, pp.157-164, 2006.
DOI : 10.1016/j.ijpharm.2006.04.007

S. Peltier, J. Oger, F. Lagarce, W. Couet, and J. Benoi-?-t, Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006.
DOI : 10.1007/s11095-006-0022-2

S. Dunn, A. Brindley, S. Davis, M. Davies, and L. Illum, Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution, Pharmaceutical Research, vol.11, issue.7, pp.1016-1022, 1994.
DOI : 10.1023/A:1018939521589

B. Gonzalez, R. Boess, F. Durr, E. Schaub, N. Bittner et al., In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes, International Journal of Pharmaceutics, vol.279, issue.1-2, pp.27-31, 2004.
DOI : 10.1016/j.ijpharm.2004.04.010

S. Top, A. Vessieres, C. Cabestaing, I. Laios, G. Leclercq et al., Studies on organometallic selective estrogen receptor modulators. (SERMs) Dual activity in the hydroxyferrocifen series, J Organomet Chem, pp.637-639500, 2001.

R. Sutherland, C. Watts, R. Hall, and P. Ruenitz, Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells, Journal of Steroid Biochemistry, vol.27, issue.4-6, pp.4-6891, 1987.
DOI : 10.1016/0022-4731(87)90165-8

D. Yao, F. Zhang, L. Yu, Y. Yang, R. Van-breemen et al., -Quinones, Chemical Research in Toxicology, vol.14, issue.12
DOI : 10.1021/tx010137i

URL : https://hal.archives-ouvertes.fr/in2p3-00509098

P. Fan, F. Zhang, and J. Bolton, 4-Hydroxylated Metabolites of the Antiestrogens Tamoxifen and Toremifene Are Metabolized to Unusually Stable Quinone Methides, Chemical Research in Toxicology, vol.13, issue.1, pp.1643-165345, 2000.
DOI : 10.1021/tx990144v

F. Zhang, P. Fan, X. Liu, L. Shen, R. Van-breemen et al., -quinone, Chemical Research in Toxicology, vol.13, issue.1, pp.53-62, 2000.
DOI : 10.1021/tx990145n

URL : https://hal.archives-ouvertes.fr/hal-01258459

D. Osella, M. Ferrali, P. Zanello, F. Laschi, M. Fontani et al., On the mechanism of the antitumor activity of ferrocenium derivatives, Inorganica Chimica Acta, vol.306, issue.1, pp.42-48, 2000.
DOI : 10.1016/S0020-1693(00)00147-X

J. Wilson, Antioxidant defense of the brain: a role for astrocytes, Canadian Journal of Physiology and Pharmacology, vol.75, issue.10-11, pp.10-111149, 1997.
DOI : 10.1139/y97-146

B. Juurlink, Response of Glial Cells to Ischemia: Roles of Reactive Oxygen Species and Glutathione, Neuroscience & Biobehavioral Reviews, vol.21, issue.2, pp.151-166, 1997.
DOI : 10.1016/S0149-7634(96)00005-X

S. Peuchen, J. Bolanos, S. Heales, A. Almeida, M. Duchen et al., Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system, Progress in Neurobiology, vol.52, issue.4, pp.261-281, 1997.
DOI : 10.1016/S0301-0082(97)00010-5

R. Dringen, Metabolism and functions of glutathione in brain, Progress in Neurobiology, vol.62, issue.6, pp.649-671, 2000.
DOI : 10.1016/S0301-0082(99)00060-X

D. Woodcock, M. Linsenmeyer, G. Chojnowski, A. Kriegler, V. Nink et al., Reversal of multidrug resistance by surfactants, British Journal of Cancer, vol.66, issue.1, pp.62-68, 1992.
DOI : 10.1038/bjc.1992.217